Back to Search Start Over

Recent advances in understanding and treating chronic granulomatous disease [version 1; referees: 4 approved]

Authors :
Andrew Gennery
Author Affiliations :
<relatesTo>1</relatesTo>Paediatric Immunology and Haematopoietic Stem Cell Transplantation, Great North Childrens’ Hospital, Newcastle upon Tyne, UK<br /><relatesTo>2</relatesTo>Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
Source :
F1000Research. 6:F1000 Faculty Rev-1427
Publication Year :
2017
Publisher :
London, UK: F1000 Research Limited, 2017.

Abstract

A number of recent advances have been made in the epidemiology and treatment of chronic granulomatous disease. Several reports from developing regions describe the presentations and progress of local populations, highlighting complications due to Bacillus Calmette–Guérin vaccination. A number of new reports describe complications of chronic granulomatous disease in adult patients, as more survivors reach adulthood. The complications experienced by X-linked carriers are particularly highlighted in three new reports, confirming that infection and inflammatory or autoimmune conditions are more common and severe than previously recognised. Finally, definitive treatment with haematopoietic stem cell transplantation and gene therapy is reviewed.

Details

ISSN :
20461402
Volume :
6
Database :
F1000Research
Journal :
F1000Research
Notes :
Editorial Note on the Review Process F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version). The referees who approved this article are: John Gallin, National Institutes of Health, Bethesda, MD, USA No competing interests were disclosed. Dirk Roos, Sanquin Research, Amsterdam, Netherlands Competing interests: Andrew Gennery wrote two chapters for a book edited by Dirk Roos Andrea Finocchi, University of Rome Tor Vergata/Bambino Gesù Children's Hospital, Unit of Immunoinfectivology, Rome, Italy No competing interests were disclosed. Nizar Mahlaoui, Immuno-Haematology and Rheumatology Unit, Necker Enfants Malades Hospital, University Paris Descartes, Paris, France Competing interests: Nizar Mahlaoui and Andrew Gennery have previously collaborated on large multicentre studies for hematopoietic cell transplantation (PMID: 28392333, 25595268) and are both on the board of the European Society for Immunodeficiencies., , [version 1; referees: 4 approved]
Publication Type :
Academic Journal
Accession number :
edsfor.10.12688.f1000research.11789.1
Document Type :
review
Full Text :
https://doi.org/10.12688/f1000research.11789.1